Iconovo AB (publ) (ICO.ST)
SEK 4.17
(-2.11%)
SEK 4.17
(-2.11%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.72 Million SEK | -22.99% |
| 2022 | 10.03 Million SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 2 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 3.28 Million SEK | 44.74% |
| 2024 Q1 | 9.59 Million SEK | 24.14% |
| 2024 Q2 | 5.52 Million SEK | -42.36% |
| 2023 FY | 7.72 Million SEK | -22.99% |
| 2023 Q3 | 8.32 Million SEK | -6.6% |
| 2023 Q2 | 8.91 Million SEK | -6.13% |
| 2023 Q4 | 7.72 Million SEK | -7.23% |
| 2023 Q1 | 9.49 Million SEK | -5.32% |
| 2022 Q2 | 11 Million SEK | 37.12% |
| 2022 Q4 | 10.03 Million SEK | -5.42% |
| 2022 FY | 10.03 Million SEK | 0.0% |
| 2022 Q1 | 8.02 Million SEK | 0.0% |
| 2022 Q3 | 10.6 Million SEK | -3.66% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 FY | 2 Million SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.521% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.521% |
| Arcoma AB | 3.87 Million SEK | -99.455% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 96.686% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.583% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 95.349% |
| CellaVision AB (publ) | 64.7 Million SEK | 88.061% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -1601.522% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -329.162% |
| Duearity AB (publ) | 10.58 Million SEK | 27.0% |
| Dignitana AB (publ) | 19.1 Million SEK | 59.564% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -48.556% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.904% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 6.36% |
| Integrum AB (publ) | 6.42 Million SEK | -20.247% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -3649.519% |
| Mentice AB (publ) | 9.55 Million SEK | 19.17% |
| OssDsign AB (publ) | 3.15 Million SEK | -145.235% |
| Paxman AB (publ) | 13.57 Million SEK | 43.074% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 62.737% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -13.652% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 75.699% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -79.399% |
| Senzime AB (publ) | 11.46 Million SEK | 32.639% |
| SpectraCure AB (publ) | 6.71 Million SEK | -15.005% |
| Stille AB | 62.94 Million SEK | 87.727% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.63% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 75.427% |